Regional astrocyte dysregulation and altered glymphatic-related markers in Alzheimer's disease frontal cortex.
H, A., XP, L., ER, D.N., K, K., L, C., MT, P., IP, T., H, W., & M, P. (2026). Regional astrocyte dysregulation and altered glymphatic-related markers in Alzheimer's disease frontal cortex.. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71745
H A, XP L, ER DN, K K, L C, MT P, et al. Regional astrocyte dysregulation and altered glymphatic-related markers in Alzheimer's disease frontal cortex.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026; doi: 10.1002/alz.71745
H A, XP L, ER DN, et al. Regional astrocyte dysregulation and altered glymphatic-related markers in Alzheimer's disease frontal cortex.[J]. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. DOI: 10.1002/alz.71745.
@article{h2026,
author = {Alexopoulos H and Louka XP and De Natale ER and Koutroubi K and Cashmore L and Panayotacopoulou MT and Trougakos IP and Wilson H and Politis M},
title = {Regional astrocyte dysregulation and altered glymphatic-related markers in Alzheimer's disease frontal cortex.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.71745},
note = {PMID: 42598755},
}
TY - JOUR AU - Alexopoulos H AU - Louka XP AU - De Natale ER AU - Koutroubi K AU - Cashmore L AU - Panayotacopoulou MT AU - Trougakos IP AU - Wilson H AU - Politis M TI - Regional astrocyte dysregulation and altered glymphatic-related markers in Alzheimer's disease frontal cortex. T2 - Alzheimer's & dementia : the journal of the Alzheimer's Association PY - 2026 DO - 10.1002/alz.71745 AN - PMID:42598755 ER -
INTRODUCTION: Astrocyte dysfunction is central to Alzheimer's disease (AD), yet expression patterns of astrocytic markers remain poorly defined. We measured Aquaporin-4 (AQP4) and glial fibrillary acidic protein (GFAP) in post-mortem frontal cortex of AD patients and controls across BrainNet Europe (BNE) stages. METHODS: We assessed marker expression across gray and white matter with immunohistochemistry and immunofluorescence. RESULTS: In AD, gray-matter AQP4 area-fraction did not differ significantly overall by immunohistochemistry, while a stage-dependent increase emerged by BNE VI in both gray and white matter. AQP4/amyloid-β (Aβ) and AQP4/tau ratios were significantly reduced, consistent with reduced AQP4 retention relative to local proteinopathy burden. GFAP intensity was significantly decreased in both gray and white matter of AD patients, with disorganized peri-plaque morphology in gray matter. DISCUSSION: These findings reveal compartment- and stage-specific astrocytic dysregulation in AD frontal cortex and identify local loss of AQP4 around proteinopathy. They support investigation of astrocyte/glymphatic-related pathways as biomarkers and therapeutic targets.